The clinical use of colony stimulating factors. NLM AIDSLINE Important note: Information in this article was accurate in 1992. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


The clinical use of colony stimulating factors.

Annu Rev Immunol. 1991;9:159-91. Unique Identifier : AIDSLINE MED/92000500
Moore MA; James Ewing Laboratory of Developmental Hematopoiesis, Memorial; Sloan-Kettering Cancer Center, New York, New York.

Abstract: Colony stimulating factors and interleukins regulate proliferation, differentiation, and functional activation of hematopoietic cells of multiple lineages. These hematopoietic growth factors are proving effective in vivo in stimulation of granulopoiesis in clinical situations associated with myelosuppression. G-CSF and GM-CSF promote accelerated granulocyte recovery following chemotherapy, or allogeneic or autologous bone marrow transplantation, in patients with cancer. In congenital defects of granulocyte production or in acquired disorders such as idiopathic neutropenia or aplastic anemia, CSF administration can lead to recovery of functioning granulocytes. This has resulted in a reduction in the morbidity and mortality associated with these diseases and now permits both a dose and a schedule intensification of chemotherapy. In myeloid leukemia and myelodysplastic syndromes, CSF treatment, particularly G-CSF, has proved effective for certain patients in improving neutrophil, platelet, and occasionally red cell production while reducing blast cells. The recombinant growth factors are generally well tolerated with few limiting toxicities at dose levels that effectively stimulate hematopoiesis.
Keywords: Acquired Immunodeficiency Syndrome/DRUG THERAPY Anemia, Aplastic/DRUG THERAPY Antineoplastic Agents/ADVERSE EFFECTS Bone Marrow Transplantation Colony-Stimulating Factors/ADVERSE EFFECTS/*THERAPEUTIC USE Hematopoiesis/DRUG EFFECTS Human Myelodysplastic Syndromes/DRUG THERAPY Neoplasms/DRUG THERAPY Neutropenia/DRUG THERAPY JOURNAL ARTICLE REVIEW REVIEW, ACADEMIC

KWDacquiredimmunodeficiencysyndrome/drugtherapyanemia,aplastic/drugtherapyantineoplasticagents/adverseeffectsbonemarrowtransplantationcolony-stimulatingfactors/adverseeffects/KWDtherapeuticusehematopoiesis/drugeffectshumanmyelodysplasticsyndromes/drugtherapyneoplasms/drugtherapyneutropenia/drugtherapyjournalarticlereviewreview,academic
920130
M9210742

Copyright © 1992 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1992. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1992. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .